Orb1220849-500mg | Menthone [10458-14-7] Clinisciences

Menthone

SKU: orb1220849

Description

Menthone has anti-inflammary activity it can suppress the lipopolysaccharide (LPS)-induced proinflammatory cytokines interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha)as well as nuclear factor kappaB (NF-kB).

Images & Validation

−

Key Properties

−

CAS Number	10458-14-7
MW	154.25
Purity	>98% (HPLC)
Formula	C₁₀H₁₈O
SMILES	CC(C)C1CCC(C)CC1=O
Target	TNF
Solubility	In Vitro: DMSO : 100 mg/mL (648.30 mM)

Bioactivity

−

In Vivo	Animal model: OVA-sensitized and challenged allergic asthmatic inflammation mouse model. Dosage: 8-200 mg/kg. Administration: i. g. , daily, 5 weeks. Result: Reversed the allergic inflammation status through at medium and high doses. Decreased total cell number and eosinophilia into BALF. Increased the percentage of monocytes/macrophages and Th1 (IL-2+IFN-γ)/Th2 (IL-4+IL-5) cytokine secretion ratio in BALF. Decreased the levels of otaxin and protein in BALF and reduced the release of β-hexosaminidase from lung mast cells. Inhibited CC receptor 3 and CXC receptor 1 gene expression levels. Animal model: CIA mouse model. Dosage: 100 mg/kg. Administration: Articulus injection, 14 days. Result: Decreased degree of posterior palm swelling and alleviated the inflammation in the local knuckles. Increased the levels of serum Creactive protein (CRP). Decreased the levels of ISGs (Ifit1, Isg15, and Mx1) and proinflammatory cytokines (TNF-α, IL-6, and IL-1β) in the finger joint tissues of the mice. Decreased the number of Th1 and Th17 cells. Decreased the levels of T-bet and RORγT gene transcription and increased the levels of GATA3 and Foxp3.
In Vitro	Western blot analysis. Cell line: 2fTGH. Concentration: 100 μM. Incubation time: 24 h. Result: Decreased the protein levels of these two ISGs (IFIT1 and PKR) induced by IFN-α. Reduced the levels of p-STAT1 in the nucleus. Attenuated menthoneinduced degradation of Tyk2 protein by MG132.Upregulated K48-linked/K63-linked polyubiquitination of Tyk2.

In Vivo

Animal model: OVA-sensitized and challenged allergic asthmatic inflammation mouse model. Dosage: 8-200 mg/kg. Administration: i. g. , daily, 5 weeks. Result: Reversed the allergic inflammation status through at medium and high doses. Decreased total cell number and eosinophilia into BALF. Increased the percentage of monocytes/macrophages and Th1 (IL-2+IFN-γ)/Th2 (IL-4+IL-5) cytokine secretion ratio in BALF. Decreased the levels of otaxin and protein in BALF and reduced the release of β-hexosaminidase from lung mast cells. Inhibited CC receptor 3 and CXC receptor 1 gene expression levels. Animal model: CIA mouse model. Dosage: 100 mg/kg. Administration: Articulus injection, 14 days. Result: Decreased degree of posterior palm swelling and alleviated the inflammation in the local knuckles. Increased the levels of serum Creactive protein (CRP). Decreased the levels of ISGs (Ifit1, Isg15, and Mx1) and proinflammatory cytokines (TNF-α, IL-6, and IL-1β) in the finger joint tissues of the mice. Decreased the number of Th1 and Th17 cells. Decreased the levels of T-bet and RORγT gene transcription and increased the levels of GATA3 and Foxp3.

In Vitro

Western blot analysis. Cell line: 2fTGH. Concentration: 100 μM. Incubation time: 24 h. Result: Decreased the protein levels of these two ISGs (IFIT1 and PKR) induced by IFN-α. Reduced the levels of p-STAT1 in the nucleus. Attenuated menthoneinduced degradation of Tyk2 protein by MG132.Upregulated K48-linked/K63-linked polyubiquitination of Tyk2.

Storage & Handling

−

Storage	Storage temperature: -20°C. Stability: ≥ 2 years
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

.carousel__track {display: flex;} .carousel__track li {list-style: none;}.product-image {display: flex;align-items: center;}.product-image-wrapper {width: 21%;}.product-image-description {width: 90%;}#reviews {display: none;}

Menthone [10458-14-7]